The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Take proper precautions and seek timely treatment!
The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
